Investor Relations

Investor Relations

News

Month Year

Month Year

Chemomab Therapeutics to Discuss Fourth Quarter and Full-Year 2022 Financial Results and Provide a Business Update

March 17, 2023
Chemomab to Present at the Oppenheimer 33rd Annual Healthcare Conference

March 06, 2023
Chemomab Announces FDA Clearance of Investigational New Drug Application for Phase 2 Clinical Trial of CM-101 in Patients with Systemic Sclerosis

February 21, 2023
Chemomab Reports Top-Line Results from CM-101 Phase 2a Liver Fibrosis Biomarker Trial in NASH Patients

January 03, 2023
Chemomab Reports Independent Drug Monitoring Committee Safety Review of CM-101 Phase 2 Trial in Primary Sclerosing Cholangitis

December 21, 2022
Chemomab Announces Appointment of Mitchell L. Jones, MD, PhD as Vice President of Corporate Development & Strategy

November 30, 2022
Chemomab Announces Appointment of Matthew Frankel, MD, MBA as Chief Medical Officer

November 14, 2022
Chemomab Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update

November 11, 2022
Chemomab Presents Clinical Data from Investigator-Initiated Study Showing CM-101 Reduced Inflammatory and Fibrogenesis-Related Biomarkers in Patients with Severe Lung Injury Derived from Covid-19

November 09, 2022
Chemomab Presents Preclinical Data at AASLD The Liver Meeting® 2022 Highlighting Key Role of CCL24 in Pathophysiology of Primary Sclerosing Cholangitis

November 07, 2022